Strong Full-Year and Quarterly Revenue Growth
Q4 revenue of $38.5M, up 32% year-over-year; full-year 2025 revenue $145.9M, up 40% year-over-year.
Material ARR Expansion
Annual recurring revenue (ARR) of $120.5M at December 31, 2025, reflecting 21% year-over-year growth and management guidance for ARR to exit 2026 at ~$145M–$150M (20%–25% growth).
RPO Growth and Backlog
Remaining performance obligation (RPO) of $293.4M at Q4-end, up 13% year-over-year from $259.1M, and record units backlog entering 2026.
Profitability Improvement
Five consecutive quarters of positive adjusted EBITDA; full-year adjusted EBITDA of $11.1M (7.6% margin) in 2025 versus a $21M loss in 2024 — a ~$32M improvement.
Stronger Cash Position and Cash Generation
Cash, cash equivalents and marketable securities increased sequentially by $12.8M in Q4 to $69M; full-year 2025 operating cash generation ~$18.7M with improved collections and working capital discipline.
Deployment Scale and Usage Metrics
8,000 systems deployed screening over 4M people per day; since product launch, over 4 billion people screened.
Customer Growth and Market Penetration
Added over 60 new customers in Q4 and now serve over 1,200 customers globally; added 65 new education customers in 2025 and 65 new sports & live entertainment customers in 2025.
Product Momentum and Cross-Sell
Early traction for eXpedite autonomous bag screening: 65 customers (~5% of customer base), with 16 brand-new customers buying eXpedite in Q4 and 11 buying it alongside Express, supporting attach rates and multi-product relationships.
Raised 2026 Guidance
Increased full-year 2026 revenue guidance to $172M–$178M (up from $160M–$165M), modeling ~18%–22% year-over-year revenue growth and expecting >10,000 deployed units by year-end 2026.
Strategic Partnerships and Market Validation
Designated preferred provider by the American Hospital Association, new notable customer wins across healthcare, sports, enterprise and education, and announced contract manufacturing ramp with Plexus (on track for H2 2026).